PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC

The goal of this clinical trial is to evaluate the clinical value of ctDNA testing in guiding the optimization of immunochemotherapy cycles during induction treatment for resectable patients with NSCLC. The main questions it aims to answer are: * Does ctDNA clearance indicate pathological complete response? * Are additional cycles of immunochemotherapy necessary for patients who have ctDNA clearance after initial cycles of treatment? Researchers will use ctDNA dynamics to guide the cycles of induction treatment to see if some patients can avoid excessive cycles of treatment.

NCT Number	NCT06977074
Lead Sponsor	Sun Yat-sen University
Conditions	Non-small Cell Lung Cancer (NSCLC)
Enrollment	83 participants
Start Date	2025-05-10
Primary Completion	2028-05-10 (estimated)
Study Completion	2030-05-10 (estimated)
Updated on ClinicalTrials.gov	2025-05-23